These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 12960733)
61. Progress in the development and acquisition of anticancer agents from marine sources. Amador ML; Jimeno J; Paz-Ares L; Cortes-Funes H; Hidalgo M Ann Oncol; 2003 Nov; 14(11):1607-15. PubMed ID: 14581267 [No Abstract] [Full Text] [Related]
62. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Vermeir M; Hemeryck A; Cuyckens F; Francesch A; Bockx M; Van Houdt J; Steemans K; Mannens G; Avilés P; De Coster R Biochem Pharmacol; 2009 May; 77(10):1642-54. PubMed ID: 19426702 [TBL] [Abstract][Full Text] [Related]
63. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Beumer JH; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O Curr Clin Pharmacol; 2009 Jan; 4(1):38-42. PubMed ID: 19149499 [TBL] [Abstract][Full Text] [Related]
65. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Le Cesne A; Reichardt P Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310 [TBL] [Abstract][Full Text] [Related]
66. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience. Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694 [TBL] [Abstract][Full Text] [Related]
67. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213 [TBL] [Abstract][Full Text] [Related]
68. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246 [TBL] [Abstract][Full Text] [Related]
69. Trabectedin's contribution to the treatment of sarcomas. Blay JY Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729 [TBL] [Abstract][Full Text] [Related]
71. Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues. D'Incalci M Eur J Cancer; 2002 Jul; 38(10):1297. PubMed ID: 12091058 [No Abstract] [Full Text] [Related]
72. ET-743: more than an innovative mechanism of action. Scotto KW Anticancer Drugs; 2002 May; 13 Suppl 1():S3-6. PubMed ID: 12173491 [TBL] [Abstract][Full Text] [Related]
73. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects. Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575 [No Abstract] [Full Text] [Related]
74. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573 [TBL] [Abstract][Full Text] [Related]
76. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695 [TBL] [Abstract][Full Text] [Related]
78. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. Ferrandina G; Salutari V; Vincenzi B; Marinaccio M; Naglieri E; Loizzi V; Carpano S; Amadio G; Tonini G; Scambia G; Lorusso D Gynecol Oncol; 2013 Sep; 130(3):505-10. PubMed ID: 23774301 [TBL] [Abstract][Full Text] [Related]
79. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Blay JY; Le Cesne A; Verweij J; Scurr M; Seynaeve C; Bonvalot S; Hogendoorn P; Jimeno J; Evrard V; van Glabbeke M; Judson I Eur J Cancer; 2004 Jun; 40(9):1327-31. PubMed ID: 15177491 [TBL] [Abstract][Full Text] [Related]